BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei
3/12/2013 12:05:50 PM
More...
|
BioAlliance Pharma: Progress in the Development of Loramyc(R) in Japan Towards its Registration by the Partner Sosei Co., Ltd.
7/2/2012 12:31:19 PM
More...
|
BioAlliance Pharma Expands its Loramyc(R) Franchise in Japan With Sosei Co., Ltd. in a Deal Valued up to 18.5M$
5/11/2011 9:58:06 AM
More...
|
BioAlliance Expands its Loramyc(R) Franchise in Japan with Sosei Co., Ltd. in a Deal Valued up to $18.5 Million
5/11/2011 6:43:57 AM
More...
|
Novartis AG, Sosei Co., Ltd. COPD Drug Phase III Trial Meets Primary Endpoint
4/19/2011 7:11:21 AM
More...
|
Sosei Co., Ltd. Agrees Terms With ASKA Pharmaceutical for Commercialization of SOH-075 (NorLevo(R))
10/22/2008 9:38:52 AM
More...
|
Sosei Co., Ltd. Announces Outcome of Strategy Review
5/14/2008 11:35:19 AM
More...
|
Sosei Co., Ltd. Announces Start of AD 923 Phase III Studies in Europe
2/12/2008 7:22:00 AM
More...
|
Sosei Co., Ltd. and Vectura Group plc Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
11/15/2007 7:19:46 AM
More...
|
Sosei Co., Ltd. Announces Start of SD118 Phase I Studies
5/29/2007 10:49:30 AM
More...
|
|